Despite ongoing advancements in genomics, artificial intelligence, and precision medicine, clinical trial success rates have remained low, with approximately 90-95% of drug candidates failing during ...

Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth ...

Bristol Myers Squibb has said it is the first life sciences company to buy a new AI supercomputing infrastructure blueprint ...

In what is thought to be South Korea's largest biopharma acquisition to date, Samsung Biologics has agreed to buy PolyPeptide ...